ClinicalTrials.gg
CompletedNCT07440524Updated Oct 15, 2026

A Phase 2 Trial of JKN24011 in COPD

A Phase 2 interventional study of JKN24011 and Placebo in COPD (Chronic Obstructive Pulmonary Disease), sponsored by Joincare Pharmaceutical Group Industry Co., Ltd. Completed at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Joincare Pharmaceutical Group Industry Co., Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Aug 2024, registered Feb 2026).
Updated Oct 15, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 111 open to participants now, 128 under way, 16 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Enrollment
128th of 289
215 · median 160
Started
2024
with 33 others
Phase 2
33 of 407
13 open now
Registered
375th of 407
by date

Among the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 128th largest by enrollment of the 289 interventional ones that give a count, is one of 34 that started in 2024, is one of 33 in phase 2, and was the 375th registered.

Pulmonary Disease, Chronic Obstructive

5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

111 of the 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 407 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Subcutaneous JKN24011 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Read the detailed description

JKN24011 targets TSLP

03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)

Keywords

  • JKN2401
  • JKN24011
  • TSLP
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written ; able and willing to comply with study procedures.
  • Adults with documented diagnosis and medical history consistent with guideline criteria.
  • Relevant exposure history consistent with COPD (e.g., smoking and/or biomass exposure).
  • On stable, guideline-based maintenance COPD therapy prior to randomization, per investigator judgment.
  • Protocol-defined exacerbation history, symptom burden, and lung function at screening.

Exclusion criteria

Exclusion Criteria:

  • Current or past asthma, or other respiratory disease that may confound assessment.
  • Clinically significant uncontrolled comorbidities that increase risk or interfere with participation/outcomes.
  • Immunodeficiency/immune dysregulation, active disease requiring systemic , or significant opportunistic infection history.
  • Active clinically significant infection or recent infection requiring systemic therapy; recent protocol-defined exacerbation.
  • Current/recent (except low-risk, adequately treated cancers per protocol) or clinically significant abnormal screening labs.
  • Prohibited recent vaccines or therapies, prior relevant biologic/targeted therapy exposure, severe to biologics/IMP, pregnancy/breastfeeding, or inability to comply (including substance abuse), per investigator judgment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
215 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo Injection, SC

    Other: Placebo

  • Experimental
    JKN24011 A

    JKN24011,SC,DOSE A

    Biological: JKN24011

  • Experimental
    JKN24011 B

    JKN24011, SC, DOSE B

    Biological: JKN24011

Interventions

  • BiologicalJKN24011

    JKN24011 subcutaneous injection,Q4W

  • OtherPlacebo

    Placebo subcutaneous injection,Q4W

06

What researchers measure

Primary outcomes

  1. Annualised rate of moderate or severe COPD exacerbations

    Time frame: Through the 52-week treatment period

  2. Annualised rate of moderate or severe COPD exacerbations

    Time frame: Through the 28-week treatment period

07

Study locations

1 site
  • Huadong Hospital, Fudan University
    Shanghai, 200040, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Apr 2026, 20 months.

Of 119 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 20 months is above that.

Counting every sponsor, half of 166 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

Completion moved once since we started tracking on Sep 25, 2026: May 2026 → Apr 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Feb 27, 2026
StartActual
Aug 1, 2024
Primary completionActual
Apr 2, 2026
CompletionActual
Apr 2, 2026was May 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 15, 2026
Study completion
May 2026→Apr 2, 2026 (actual)
Oct 15, 2026
Primary outcomes
1 added
What changed in the outcomes
  • AddedAnnualised rate of moderate or severe COPD exacerbationsTime frame: Through the 28-week treatment period
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Active, not recruiting→Completed
    Study completion May 2026→Apr 2, 2026 (now actual)
    Primary outcomes 1 added
    What changed in the outcomes
    • AddedAnnualised rate of moderate or severe COPD exacerbationsTime frame: Through the 28-week treatment period
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07440524
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Aug 1, 2024
Primary completion
Apr 2, 2026
Completion
Apr 2, 2026
Last update
Oct 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion